Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

Executive Summary

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Advertisement

Related Content

Nektar Turns Up The Heat On Partnering Talks For NKTR-181
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Scrip Asks… What Will Happen In Orphan Drug Pricing In The Next Five Years?
Takeda Extends PRA Alliance To Japan With New JV
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
Pipeline Watch: Three Approvals, Five Filings And One Launch
Deal Watch: Flagship Ventures Doubles Down On Microbiome
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
Immuno-Oncology Veteran Rachel Humphrey Joins CytomX
Bristol-Myers commits up to $1.2bn in CytomX deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel